- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02759406
Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
April 28, 2016 updated by: Palmaz Scientific
This is a six (6) month, randomized, un-blinded, study to assess the safety and performance of the Palmaz Mach-5 Grooved Coronary Stent System vs. the Palmaz Bare Metal Coronary Stent System.
Study Overview
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patients of any race greater than or equal to 18 years and of legal consent
- Patients must be willing to comply with the specified follow-up evaluation schedule
- Patients who sign an informed consent (signed and dated) prior to any study-related evaluation or procedure.
- Patients who are willing to undergo a follow-up coronary angiogram and Endovascular Imaging via Optical Coherence Tomography
- Patients willing to be maintained on Aspirin and Clopidogrel bisulfate (Plavix) for ninety (90) days post procedure.
- Patients with a de novo coronary lesion causing angina and/or a positive function test
- Patients who are eligible for percutaneous coronary interventions
- Low risk NSTEMI defined as patients with ACS, unstable angina, positive cardiac biomarkers and hemodynamically stable as assessed by the Investigator.
- Patients with an acceptable risk for coronary bypass graft surgery (CABG)
Intra-Procedure Angiographic Criteria:
- Single de novo target lesion >50% diameter stenosis by angiography
- Single target vessel 2.75 to 3.25 mm diameter
- Lesion length of 14 to 20mm which is suitable for Palmaz Mach-5 Grooved Coronary Stent System or the Palmaz Bare Metal Coronary Stent System.
Exclusion Criteria:
- Known allergy or sensitivity to cobalt chromium (CoCr) alloy or its components.
- Known sensitivity or allergy to aspirin, radiographic contract agents (that cannot be pre-treated adequately).
- Patients unable to tolerate anticoagulant therapy or antiplatelet therapy.
- History of bleeding or known coagulopathy.
- Patients with thrombocytopenia and or neutropenia.
- More than one stenosis >50% in target vessel.
- Lesion in aortic ostium.
- Left main or LAD, CX lesions within 2-mm from the origin.
- Ejection Fraction <45%.
- STEMI in evolution.
- Disabling stroke within previous 30 days.
- Patients currently enrolled in another Investigational device or drug study.
- Previous enrollment in this study.
- Women who are currently pregnant. (A negative pregnancy test for female subjects of child bearing potential is required within 24 hours of procedure.)
- Known or suspected active systemic infection.
- Evidence of severe or uncontrolled systemic diseases, including chronic renal insufficiency, or any condition which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mach-5 Grooved
grooved
|
|
Experimental: Mach 5 Bare Metal
bare metal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
late lumen loss rate by Quantative/ Qualtative Cornary Angiographia
Time Frame: 6 month
|
6 month
|
total percentage of strut coverage by Optical Coherence Tomography analysis
Time Frame: 6 month
|
6 month
|
Primary safety endpoint is the occurrence of adverse events associated with the Investigational and comparator devices.
Time Frame: 6 month
|
6 month
|
binary restenosis rate by Quantative/ Qualtative Cornary Angiographia
Time Frame: 6 month
|
6 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2013
Primary Completion (Actual)
May 1, 2015
Study Completion (Actual)
June 1, 2015
Study Registration Dates
First Submitted
April 27, 2016
First Submitted That Met QC Criteria
April 28, 2016
First Posted (Estimate)
May 3, 2016
Study Record Updates
Last Update Posted (Estimate)
May 3, 2016
Last Update Submitted That Met QC Criteria
April 28, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Mach-5
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Heart Disease
-
Genzyme, a Sanofi CompanyTerminatedIschemic Heart Disease | Ischemic Cardiomyopathy | Ischemic Heart FailureBelgium, France, Germany, Italy, Switzerland, United Kingdom
-
Cardiocentro TicinoTerminatedChronic Ischemic Heart DiseaseSwitzerland
-
University of AlbertaRecruitingCoronary Artery Disease | Stable Ischemic Heart Disease | Beta-blocker TherapyCanada
-
Gerencia de Atención Primaria, MadridServicio Canario de Salud; Avedis Donabedian Research InstituteCompletedIschemic Heart Disease ChronicSpain
-
Michael SekelaCompletedChronic Ischemic Heart DiseaseUnited States
-
University of PecsCompleted
-
Rigshospitalet, DenmarkNot yet recruitingChronic Ischemic Heart DiseaseDenmark
-
The University of Texas Health Science Center,...National Heart, Lung, and Blood Institute (NHLBI); Cardiovascular Cell Therapy...CompletedIschemic Cardiomyopathy | Left Ventricular Dysfunction | Angina | Chronic Ischemic Heart DiseaseUnited States
-
Affiliated Hospital to Academy of Military Medical...Ivy Institute of Stem Cells Co. LtdUnknownHeart Failure | Angina | Chronic Ischemic Heart DiseaseChina
-
University of EdinburghUnknown
Clinical Trials on coronary stent
-
Medinol Ltd.CompletedIschemic Heart DiseaseIsrael, Sweden, Belgium, Germany
-
Odense University HospitalCompletedIschemic Heart Disease | Percutaneous Coronary Intervention | Coronary AtherosclerosisDenmark
-
Abbott Medical DevicesCompleted
-
A.O. Ospedale Papa Giovanni XXIIIMedtronic; Case Western Reserve UniversityCompletedAcute Myocardial InfarctionItaly
-
CCRF Consulting Co., Ltd.Peking University First Hospital; Terumo Medical(shanghai) Co.,Ltd.UnknownFree Rate of Cardiac or Cerebrovascular Events | Transradial-transfemoral Coronary Interventions ComparisonChina
-
BioSync Scientific Pvt. Ltd.Cardialysis BV; MIV Therapeutics Inc.UnknownCoronary Artery Disease
-
Rigshospitalet, DenmarkCompleted
-
NHS National Waiting Times Centre BoardCompletedStent Thrombosis | Coronary Stent Occlusion | Coronary Artery PerforationUnited Kingdom
-
OrbusNeichCompletedCoronary Artery Disease | Coronary Artery StenosisNetherlands, Belgium, United Kingdom, France, Germany, Austria
-
Hospital Sao Lucas da PUCRSCompletedCoronary Heart Disease | Atherosclerotic Heart Disease